Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Van Hougenhouck-Tulleken, W.G. (Wesley)![]() |
|
dc.date.accessioned | 2024-07-24T10:19:12Z | |
dc.date.available | 2024-07-24T10:19:12Z | |
dc.date.issued | 2023 | |
dc.description.abstract | Anaemia, occurring in over 50% of patients with stages 3 to 5 chronic kidney disease (CKD), often causes fatigue, shortness of breath, cardiac dysfunction and cognitive impairment. The major causes include disorders of iron metabolism (both iron deficiency and iron blockade) and erythropoietin deficiency. Treatment should be aggressive, and treated to specific targets. Nutritional deficiencies should be treated first, and only once replete, should erythropoiesis-stimulating agents (EPO-stimulating agents [ESAs]) be considered. Careful consideration must be given to the adverse effects of ESAs, and prescribed only after discussion with the patient. Patients with refractory anaemia, rapidly deteriorating glomerular filtration rate (GFR), and who have stage 3–5 CKD should be referred timeously to a nephrologist. | en_US |
dc.description.department | Internal Medicine | en_US |
dc.description.librarian | am2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.uri | https://journals.co.za/journal/mp.sapj | en_US |
dc.identifier.citation | Van Hougenhouck-Tulleken, W. 2023, 'Anaemia in chronic kidney disease', South African Pharmaceutical Journal, vol. 90, no. 1, pp. 22-24, doi : 10.10520/ejc-mp_sapj_v90_n1_a7. | en_US |
dc.identifier.issn | 2221-5875 (print) | |
dc.identifier.issn | 2220-1017 (online) | |
dc.identifier.other | 10.10520/ejc-mp_sapj_v90_n1_a7 | |
dc.identifier.uri | http://hdl.handle.net/2263/97206 | |
dc.language.iso | en | en_US |
dc.publisher | Medpharm Publications | en_US |
dc.rights | © Medpharm Publications. | en_US |
dc.subject | Anaemia in chronic kidney disease (AiCKD) | en_US |
dc.subject | Haemoglobin | en_US |
dc.subject | Iron | en_US |
dc.subject | Erythropoietin | en_US |
dc.subject | Uraemic toxins | en_US |
dc.subject | Chronic kidney disease (CKD) | en_US |
dc.subject | EPO-stimulating agents (ESAs) | en_US |
dc.subject | Glomerular filtration rate (GFR) | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.title | Anaemia in chronic kidney disease | en_US |
dc.type | Article | en_US |